NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.55% | -9.03% | |||
| Total Other Revenue | 30.77% | 85.71% | |||
| Total Revenue | 1.71% | -8.78% | |||
| Cost of Revenue | 4.95% | -3.46% | |||
| Gross Profit | 0.06% | -11.26% | |||
| SG&A Expenses | 0.53% | -21.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.42% | -17.82% | |||
| Operating Income | -0.76% | 32.97% | |||
| Income Before Tax | 23.53% | 48.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.53% | 48.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.53% | 50.68% | |||
| EBIT | -0.76% | 32.97% | |||
| EBITDA | -0.96% | 33.16% | |||
| EPS Basic | 56.45% | 73.08% | |||
| Normalized Basic EPS | 75.15% | 59.97% | |||
| EPS Diluted | 56.45% | 73.08% | |||
| Normalized Diluted EPS | 75.15% | 59.97% | |||
| Average Basic Shares Outstanding | 221.21% | 63.85% | |||
| Average Diluted Shares Outstanding | 221.21% | 63.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
